OTC Markets OTCQB - Delayed Quote ? USD Bioxytran, Inc. (BIXT) Follow Compare 0.1100 0.0000 (0.00%) At close: October 18 at 4:00 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Presenting on the Emerging Growth Conference 75 Day 2 on September 26 MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 75th Emerging Growth Conference on September 25 & 26, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting GlobeNewswire ? 25 days ago ATWT SEVCF UMAC Bioxytran's Medical Breakthrough in Fighting All Viruses Breakthrough was validated in the latest journal article Galectins are essential for viral entry and a new target for drug development Carbohydrates were shown to neutralize viruses Blocking galectins could be the most efficient way to prevent and ... ACCESSWIRE ? last month BIXT 0.00% Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now MIAMI, Aug. 21, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compa GlobeNewswire ? last month CYIO SDA SDAWW Bioxytran Launches Joint Venture with the Heme Foundation for Development of Universal Oxygen Carrier The Heme Foundation and Bioxytran join forces to address the global blood supply shortage BOSTON, MASSACHUSETTS, July 18, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19, other viral diseases, and stroke, is pleased to announce a Joint Venture (the “JV”) with the Heme Foundation (“Heme” or the “Foundation”) to develop a Universal Oxygen Carrier (“UOC”) as an alternative to blood GlobeNewswire ? 3 months ago BIXT 0.00% Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 73rd Emerging Growth Conference on July 17 & 18 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companie GlobeNewswire ? 3 months ago CVKD GDTC CRVO Bioxytran’s Advisor Releases Book on Hyperbaric Oxygenation Related to Stroke & Alzheimer’s Patients BXT-25 is expected to oxygenate the brain BOSTON, MASSACHUSETTS, June 27, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing drugs to treat stroke and Alzheimer's disease, announced that Bioxtran’s Science Advisor Prof. Avraham Mayevsky’s book titled Hyperbaric Oxygenation Mitochondrial Activity and Brain Physiological Functions was published by a publishing house, Springer. It is available by eBook or Hardcover. The book is GlobeNewswire ? 3 months ago BIXT 0.00% Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now MIAMI, June 12, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 72nd Emerging Growth Conference on June 12 & 13, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compani GlobeNewswire ? 4 months ago TRGEF CVKD KASHF Presenting on the Emerging Growth Conference 70 Day 1 on May 8 Register Now MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 70th Emerging Growth Conference on May 8 & 9, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies t GlobeNewswire ? 5 months ago OWLT OWLTW IDEX Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compani GlobeNewswire ? 6 months ago GOEV GOEVW AYTU Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist 50% Lesion clearance and regression of Herpes Zoster Neuralgia within 48 – 72 hours BOSTON, MASSACHUSETTS, March 06, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, announced today the preprint in ResearchGate entitled “Association of Rapid Shingles Lesion Clearance and Regression of Herpes Zoster Neuralgia in Case Study Using Topical Galectin-3 Antagonism” showed a time lapsed GlobeNewswire ? 7 months ago BIXT 0.00% Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19 First Medicinal chemistry of an antiviral drug made of sugars BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, announced that the first patients have been treated with ProLectin-M in its dose optimization trial. ProLectin-M is intended to become a first line treatment for standard risk COVID-19 patients, but based on the broad-spectrum in v GlobeNewswire ? 7 months ago BIXT 0.00% Bioxytran Gets Broad Patent Coverage on 60+ Viruses Claims cover method of treating a viral infection with a lectin-binding carbohydrate BOSTON, MASSACHUSETTS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral diseases, announced that the U.S Patent and Trademark Office (USPTO) has published the Company’s patent application WO2023178228A1 Lectin-binding carbohydrates for treating viral infections. The pending pat GlobeNewswire ? 11 months ago BIXT 0.00% Performance Overview Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return BIXT S&P 500 YTD -26.67% +22.95% 1-Year -33.33% +34.10% 3-Year +3,448.39% +31.16%
